Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN2810 and Ipilimumab with SBRT in Locally Advanced Prostate Cancer
NCT03477864Phase 1Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2018
- Primary completion
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
01
Overview
Phase 1, open-label trial of cemiplimab and ipilimumab in prostate cancer (PCa) (3 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Incidence of adverse events up to 70 days. Planned start Dec 2018; status: withdrawn.
02
Drugs
cemiplimabipilimumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03477864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03477864.